Previous Close | 151.99 |
1-Year Change | -38.06% |
6-Months Change | -24.71% |
3-Months Change | -18.94% |
Moving Avg (50d) | 177.62 |
Moving Avg (200d) | 199.44 |
ESG Rating | - |
Exchange | NYSE |
Market Cap. | 7.8B |
Beta (3-Years) | 1.22 |
Revenue Growth (ttm) | 11.49% |
Net Profit Margin (ttm) | 11.27% |
Return On Assets (ttm) | 6.24% |
EPS (ttm) | 9.24 |
PE Ratio (ttm) | 16.45 |
Dividend Yield | % |
Asset Description: | Charles River Laboratories International, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Strong sell |
Forecast Date: | 2025-02-10 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
155.03 | 159.59 | 162.629 | 167.189 | 174.789 | 182.388 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |
Charles River Laboratories International, Inc. is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted biomedical products, outsourcing services, and animals for research and development in the pharmaceutical industry and... Wikipedia